4114 Stock Overview
A specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 4114 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Synmosa Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$33.30 |
| 52 Week High | NT$38.35 |
| 52 Week Low | NT$32.25 |
| Beta | 0.32 |
| 1 Month Change | -4.58% |
| 3 Month Change | -10.72% |
| 1 Year Change | -6.44% |
| 3 Year Change | 88.42% |
| 5 Year Change | 118.80% |
| Change since IPO | 473.27% |
Recent News & Updates
Recent updates
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?
Apr 04
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today
Mar 08Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 31Is Synmosa Biopharma (GTSM:4114) A Risky Investment?
Jan 05Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09
Shareholder Returns
| 4114 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.9% | -0.01% | -2.1% |
| 1Y | -6.4% | -2.7% | 25.6% |
Return vs Industry: 4114 underperformed the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 4114 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4114 volatility | |
|---|---|
| 4114 Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4114 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4114's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Chih-Hui Lin | www.synmosa.com.tw |
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms.
Synmosa Biopharma Corporation Fundamentals Summary
| 4114 fundamental statistics | |
|---|---|
| Market cap | NT$13.99b |
| Earnings (TTM) | NT$718.07m |
| Revenue (TTM) | NT$5.38b |
19.5x
P/E Ratio2.6x
P/S RatioIs 4114 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4114 income statement (TTM) | |
|---|---|
| Revenue | NT$5.38b |
| Cost of Revenue | NT$3.07b |
| Gross Profit | NT$2.31b |
| Other Expenses | NT$1.59b |
| Earnings | NT$718.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.71 |
| Gross Margin | 42.93% |
| Net Profit Margin | 13.36% |
| Debt/Equity Ratio | 30.2% |
How did 4114 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Synmosa Biopharma Corporation is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |
| Yijun Chen | SinoPac Securities Investment Service |